UPDATED May 19, 2024
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
---|---|---|---|---|---|---|---|---|---|---|
GMED | US$64.40 | 1.0% | 13.3% | US$8.7b | US$68.75 | PE130.5x | E40.9% | n/a | ||
STAA | US$42.70 | 0.8% | -32.5% | US$2.1b | US$52.31 | PE137.1x | E35.2% | n/a | ||
PNTG | US$23.02 | -1.6% | 83.0% | US$691.7m | US$25.50 | PE42.1x | E23.3% | n/a | ||
ALGN | US$271.50 | -0.07% | -6.7% | US$20.4b | US$340.69 | PE44.2x | E15.8% | n/a |